| Megan Veronica Daley Jones, DO | |
|
301 E City Ave, Ste 100, Bala Cynwyd, PA 19004-1738 | |
| (610) 617-0199 | |
| (610) 617-0199 |
| Full Name | Megan Veronica Daley Jones |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 301 E City Ave, Bala Cynwyd, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366880031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS018023 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Main Line Hospital Lankenau | Wynnewood, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Main Line Healthcare | 1951215201 | 894 |
News Archive
GlaxoSmithKline (GSK) and Imperial College London today announce a unique research collaboration in medical imaging. GSK will contribute funding of £28m for the construction of a new Clinical Imaging Centre, next to Hammersmith Hospital in West London, UK. Research will focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis and psychiatric diseases. In association with the Clinical Imaging Centre, GSK and Imperial have entered into a 10-year research agreement for medical imaging.
New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis and how this contributes to neurodegenerative symptoms.
An unprecedented alliance of leading scientists, health professionals, and children's and environmental health advocates agree for the first time that today's scientific evidence supports a link between exposures to toxic chemicals in air, water, food and everyday products and children's risks for neurodevelopmental disorders.
Research led by St. Jude Children's Research Hospital investigators suggests that safeguarding cell survival and maintaining a balanced immune system is just the start of the myeloid cell leukemia sequence 1 (MCL1) protein's work.
CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a "significant strategy" in the future design of anti-aging pharmaceuticals.
› Verified 4 days ago
| Entity Name | Main Line Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922077643 PECOS PAC ID: 1951215201 Enrollment ID: O20040308000373 |
News Archive
GlaxoSmithKline (GSK) and Imperial College London today announce a unique research collaboration in medical imaging. GSK will contribute funding of £28m for the construction of a new Clinical Imaging Centre, next to Hammersmith Hospital in West London, UK. Research will focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis and psychiatric diseases. In association with the Clinical Imaging Centre, GSK and Imperial have entered into a 10-year research agreement for medical imaging.
New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis and how this contributes to neurodegenerative symptoms.
An unprecedented alliance of leading scientists, health professionals, and children's and environmental health advocates agree for the first time that today's scientific evidence supports a link between exposures to toxic chemicals in air, water, food and everyday products and children's risks for neurodevelopmental disorders.
Research led by St. Jude Children's Research Hospital investigators suggests that safeguarding cell survival and maintaining a balanced immune system is just the start of the myeloid cell leukemia sequence 1 (MCL1) protein's work.
CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a "significant strategy" in the future design of anti-aging pharmaceuticals.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Veronica Daley Jones, DO 301 E City Ave, Ste 100, Bala Cynwyd, PA 19004-1738 Ph: (610) 617-0199 | Megan Veronica Daley Jones, DO 301 E City Ave, Ste 100, Bala Cynwyd, PA 19004-1738 Ph: (610) 617-0199 |
News Archive
GlaxoSmithKline (GSK) and Imperial College London today announce a unique research collaboration in medical imaging. GSK will contribute funding of £28m for the construction of a new Clinical Imaging Centre, next to Hammersmith Hospital in West London, UK. Research will focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis and psychiatric diseases. In association with the Clinical Imaging Centre, GSK and Imperial have entered into a 10-year research agreement for medical imaging.
New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis and how this contributes to neurodegenerative symptoms.
An unprecedented alliance of leading scientists, health professionals, and children's and environmental health advocates agree for the first time that today's scientific evidence supports a link between exposures to toxic chemicals in air, water, food and everyday products and children's risks for neurodevelopmental disorders.
Research led by St. Jude Children's Research Hospital investigators suggests that safeguarding cell survival and maintaining a balanced immune system is just the start of the myeloid cell leukemia sequence 1 (MCL1) protein's work.
CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a "significant strategy" in the future design of anti-aging pharmaceuticals.
› Verified 4 days ago
Dr. Tamara B Fedec, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 301 E City Ave, Suite 100, Bala Cynwyd, PA 19004 Phone: 610-617-1300 Fax: 610-617-0199 | |
Erik Christopher Thorell, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Bala Plz, Suite Il-27, Bala Cynwyd, PA 19004 Phone: 610-668-9999 | |
Craig Ross, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 111 Presidential Blvd, Suite 127, Bala Cynwyd, PA 19004 Phone: 484-438-5495 | |
Marina Yakovevna Sigidin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Bala Plaza, Suite Il-27, Bala Cynwyd, PA 19004 Phone: 610-668-9999 Fax: 610-859-8217 | |
Mr. James Angelo Lamprakos, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2 Bala Plz, Suite 600, Bala Cynwyd, PA 19004 Phone: 610-667-4463 Fax: 610-667-4764 | |
Leslie Marie Partem, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Bala Plz, Suite Il-27, Bala Cynwyd, PA 19004 Phone: 610-668-9999 |